Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen Reports Second Quarter 2021 Financial Results
August 3, 2021 4:01 PM EDTTHOUSAND OAKS, Calif., Aug. 3, 2021 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2021. Key results include:
Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia® (denosumab), Repatha® (evolocumab) and our biosimilar products MVASI® (bevacizumab-awwb) and KANJINTI® (trastuzumab-anns).GAAP earnings per share (EPS) decreased 73% to $0.81 driven by... More